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Abstract
Microvillus inclusion disease (MVID) is characterised by onset of intractable life-threatening watery diarrhoea during
infancy. Transmission electron microscopy demonstrates shortening or absence of apical microvilli, pathognomonic
microvillus inclusions in mature enterocytes and subapical accumulation of periodic acid-Schiff-positive granules
or vesicles confirming diagnosis. Mutations in MYO5B have been found to cause MVID. In two patients with MVID,
whole-exome sequencing of DNA revealed homozygous truncating mutations in STX3. Mutations in these genes
disrupt trafficking between apical cargo vesicles and the apical plasma membrane. Thus, disturbed delivery of
certain brush border membrane proteins is a common defect in MVID.
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The history of microvillus inclusion disease
In 1978, Davidson and colleagues first described five
infants with severe diarrhoea from birth and failure to
thrive [1]. The disease was identified as a congenital
enteropathy marked by villus atrophy, severe diarrhoea
with partial sodium loss and malabsorption. Further-
more, jejunal biopsies displayed in electron microscopy
(EM) cytoplasmic inclusions with brush border micro-
villi on their inside. Over the following years, the disease
was given several names: Davidson disease [1], congeni-
tal familial protracted diarrhoea with enterocyte brush-
border abnormalities, congenital microvillus atrophy [2]
and microvillus inclusion disease (MVID). The latter one
was shaped by Cutz and colleagues in 1989 [3]. This
study sets the diagnostic standard, already discussing
further possible mechanisms for the formation of micro-
villus inclusions (ectopic brush border formation at
intracellular sites [3] versus engulfment of brush border
via autophagy/macropinocytosis [1]; see also below the
paragraph on pathophysiology). The following years, an
increasing number of patients were diagnosed with MVID
and diagnostic criteria were refined [4–6]. In 2008, muta-
tions in MYO5B were identified as causal for MVID [7].
This finding initiated further research trying to unravel
the pathophysiology of MVID and the specific function
of the motor protein Myo5B in polarised epithelial cells
[8–10]. With the identification of mutations in a second
gene, STX3, causative for MVID, molecular and genetic
analyses gained pace pushing MVID to the ‘centre
stage’ of molecular paediatric research.
Clinical features of MVID
MVID patients typically present intractable watery diar-
rhoea, leading to a severe loss of body weight, and
metabolic acidosis due to bicarbonate loss [1, 3, 4, 11].
Early-onset MVID that starts within the first days after
birth can be discriminated from late-onset MVID cases
[4, 12]. The latter one becomes clinically apparent only
at the age of 2 to 3 months. In general, pregnancy was
reported to be without complications, but occasionally,
maternal polyhydramnios is present. Diarrhoea is the main,
often life-threatening symptom of MVID. Stool volumes
range between 150 and 300 ml/kg/day and respond only
slightly to bowel arrest [4].
In most cases, no additional clinical signs, such as
malformations, or other organ manifestations accompany
MVID. However, cholestatic liver disease might be present
in up to one third of patients [13], and cases of associated
renal Fanconi syndrome [14] have been reported.
Treatment aims at supplementing the fluid and nutrient
loss. Thus, life-long total parenteral nutrition (TPN) is
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generally required. No causative cure is available, but
small bowel transplantation (intestinal Tx) is able to cure
the severe diarrhoea. Both TPN and intestinal Tx come
with side effects, such as cholestasis or infections caused
by the immunosuppressive regime.
The limited therapeutic options and the severity of
the disease often lead to the patients’ death within the
first 3 years. However, patients with late-onset MVID
sometime tolerate enteral feeding. The requirement of
parenteral nutrition can be reduced to once or twice
per week [4, 6].
Genetics
Since the identification of mutations in the MYO5B gene
in 2008, an increasing number of mutations causing
MVID are described in the literature [7, 8, 12], thereby
confirming autosomal recessive inheritance of MVID.
Homozygous (mostly originating from consanguine par-
ents) and compound-heterozygous missense and nonsense
mutations (mostly from non-consanguine parents) were
reported. However, in some patients, only one heterozy-
gous mutation and no second mutation could be identi-
fied [12] upon sequencing all exons and exon-intron
boundaries. With this technique, deep intronic mutations,
mutations in regulatory regions, and deletions and du-
plications involving whole exons cannot be revealed
and may be missed. Nowadays, commercial multiplex
ligation-dependent probe amplification (MLPA) ana-
lysis is available to detect larger intragenic deletions
and duplications. Sequencing and MLPA analysis detect
biallelic mutations in >90 % of patients referred with a
clinical/histopathologic diagnosis of MVID (n = 70, our
unpublished data). Van der Velde and colleagues have
methodically characterised all currently reported muta-
tions in MYO5B and linked them to potentially im-
paired functions of the different domains of the actin
motor protein MYO5B [12].
The second gene in which MVID causing mutations
were identified was STX3 [15]. So far, two patients of
2 years of age have been reported, both with nonsense mu-
tations resulting in truncations of the apically targeted
N-ethylmaleimide-sensitive factor attachment protein
receptor (SNARE) protein syntaxin3 [15]. Genotype-
phenotype correlation with respect to MYO5B and
STX3-related MVID has not been reported so far, due
to the small number and young age of patients with
STX3 mutations.
Diagnosis
The clinical presentation of MVID is that of severe diar-
rhoea, most often starting within the first week of life.
The diarrhoea has a secretory component, which persists
even when giving nil per mouth and does not clinically
resolve upon elimination of dietary components. Villus
atrophy, brush border reduction and increased periodic
acid-Schiff (PAS) staining throughout the subapical cyto-
plasm are often found in light microscopy. Immunohisto-
chemistry for brush border components CD10 (a neutral
membrane-associated peptidase) [6, 16], Villin [17] and
Rab11a [18, 19] shows an irregular, broadened apical
signal, corresponding to abnormal subapical localization
of brush border components, which strongly raises suspi-
cion of MVID. Analysis of small intestinal biopsies by EM
remains the best tool for histological diagnosis of MVID.
EM reveals shortening or absence of brush border micro-
villi, so-called microvillus inclusions (vacuoles bearing
centripetal microvilli in about 10 % of small gut villus
enterocytes), and a subapical accumulation of different
kinds of vesicular/tubular structures, referred to as ‘PAS
positive secretory granules’ [5]—the three ultrastructural/
diagnostic hallmarks of MVID (compare Fig. 1). Differ-
ences in the abundance of these features are often
observed between villus and crypt enterocytes. While
villus enterocytes may display all three hallmarks, crypt
enterocytes generally display just secretory granules.
Only a minority of enterocytes might display the hall-
marks at the time of EM analysis, and the histological
presentation of MVID varies from patient to patient.
Additionally, increasing availability and decreasing costs
of modern genetic analysis render it a suitable tool to ver-
ify MVID diagnosis. Targeted mutational analysis of the
MYO5B and STX3 loci, high-throughput sequencing of
genes causing congenital diarrhoeas (‘gene panel’ sequen-
cing) and whole-exome sequencing should be performed.
Pathophysiology
Over the last years, several studies have added to the un-
derstanding of MVID’s pathophysiology [7–10, 15, 20–22].
Besides native biopsy material from MVID patients, the
human colorectal adenoma cell line CaCo2 has been used
as the model system in most of these studies. As this cell
line has the ability to establish enterocyte polarity in cul-
ture, it has been the basis for loss of Myo5B studies and its
impact on epithelial polarity. This approach allowed to gain
further insight into the role of Myo5B in intracellular traf-
ficking as down-regulation and knockout recapitulate the
loss of apical microvilli, loss of polarity and the accom-
panying mislocalisation of apical transporters [8, 9, 20].
This might be a crucial step for understanding MVID, as
the mislocalisation of the Na+/H+ exchanger NHE3 [20]
might account for the sodium loss diarrhoea reported from
MVID cases [23]. The identification of a second gene
causal for MVID, the t-SNARE STX3, points towards a role
of the apical exocytic pathway in epithelial cells. Both
Myo5B and Stx3 are involved in apical trafficking [15, 24].
The origin of microvillus inclusions [10, 21] was ad-
dressed as well, and hypotheses range from autophagocy-
tosed/endocytosed apical plasma membrane [1, 10, 21, 25]
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to de novo formed, intracellular apical domains [3, 19].
Conceivably, microvillus inclusions might not add much
to the pathophysiology but could rather be a secondary
effect [25] of overall disrupted epithelial polarity, since
similar structures known as ‘vacuolar apical compart-
ments (VACs)’ also occur in epithelial cancers, or follow-
ing experimental disruption of the cytoskeleton or of
intercellular contacts [26–30].
So far, secretory granules could only rarely be repro-
duced in in vitro culture [8, 15]. However, a genome-edited
CaCo2 cell line was recently published, demonstrating all
three ultrastructural hallmarks including an accumulation
of subapical vesicles. With this, better understanding of
MVID’s pathophysiology was achieved [31].
Only recently, MYO5B knockout mouse models have
been published. Despite the different genetic approaches
applied, constitutive whole organism knockout [32] and in-
ducible bowel-specific knockout [19, 25]demonstrate all
these studies MVID-like phenotypes in mice. Schneeberger
and colleagues demonstrated that organoid cultures of
murine intestinal stem cells might serve a useful tool to
test future therapies for MVID [19]. For this, crypt stem
cells obtained by endoscopic biopsies are cultured to form
‘mini-guts’ ex vivo.
Outlook
The increase in understanding the pathophysiology of
MVID will eventually allow developing targeted therapies
to treat specific symptoms, e.g. diarrhoea, and could over-
come the need to transplant the small bowel and perform
long-term parenteral nutrition. This could lead to a drastic
increase in the quality of life of MVID patients. New
therapeutic approaches could be tested on organoid cul-
tures derived from mice or patients. This, of course, re-
mains speculative at the moment, but conceivable targets
of therapy could be the disrupted epithelial polarity and
the accompanying mislocalisation of apical enzymes and
transporters.
In recent years, novel genome editing technologies,
such as CRISPR/Cas9, once again moved gene therapy
into the spotlights. Enterocyte stem cells reside at the
bottom of every crypt in the bowel [33]. Thus, all these
stem cell niches have to be targeted in order to achieve
therapeutic efficiency. Besides all still unsolved problems
of genome editing, e.g. off targets [34], crypt stem cells
niches make gene therapy rather unsuitable for MVID.
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Fig. 1 Electron micrograph of patient’s duodenal enterocytes depicting the three ultrastructural hallmarks of MVID (homozygous c.1323–2A > G
splice-site mutation in MYO5B). Black arrow heads mark the shortening or loss of apical microvilli. Subapical accumulations of tubulo-/vesicular
structures (secretory granules) are marked by black arrows. MI intracellular microvillus inclusion, Lys lysosomes. Scale bar = 2 μm
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